A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry. This is an ASCO ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

colorectal, and lung. The term can apply to multiple types of specific therapies, including chemotherapy, radiation, hormone therapy, and immunotherapy. The main goal of adjuvant cancer treatments ...

Despite recent advances in therapy, certain subtypes of colorectal cancer, such as those that are microsatellite instability ...

Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...

Administering immunotherapy in the neo-adjuvant, pre-operative setting is an emerging therapeutic option and neoadjuvant immunotherapy–based clinical trials have now been conducted in several ...

There are several anticancer developmental vaccines containing different adjuvants both in marketed and clinical development for cancer immunotherapy: those containing Tensoactive adjuvant ...

The investigational arm of the trial will consider the use of immunotherapy or targeted agents, typically used for metastatic colon cancer, to potentially increase cure rates with adjuvant therapy.